STAAR Surgical Company (NASDAQ: STAA): Enhancing Vision, Changing Lives

STAAR Surgical Company (NASDAQ: STAA), headquartered in Monrovia, California, is a prominent medical device manufacturer focused on implantable lenses for the eyes, specifically targeting the correction of myopia and treatment of cataracts. Its flagship product, the Visian ICL (Implantable Collamer Lens), has gained significant traction as an alternative to traditional laser-based vision correction procedures like LASIK, offering patients a reversible option that avoids permanent alteration of the cornea.   

STAAR is strategically positioned in the growing global market for vision correction, particularly in regions like Asia, where the prevalence of myopia is high, fueling demand for advanced eye-care solutions. Despite its strong market presence, STAAR Surgical faces competition from traditional corrective methods and emerging technologies. Additionally, the company must navigate stringent regulatory approval processes, which can impact the timing of product launches. While the stock has experienced some volatility, it remains attractive to long-term investors who are optimistic about the expanding global eye-care market and STAAR’s role within it.  

Highlights and News Update 

• On August 20th, 2024, Arthur C Butcher, a Director at STAAR Surgical Co, purchased 1,315 shares of Common Stock on August 12, 2024, at a price of US $37.99 per share, totaling US $49,956.  

• On July 31st, 2024, STAAR Surgical Company a leading developer, manufacturer, and marketer of the EVO family of Implantable Collamer(R) Lenses (EVO ICL(TM)) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024. 

• On July 15th, 2024, Morgan Stanley downgraded Staar Surgical to underweight from equal weight and lowered the price targets to $30 from a prior target of US $37 from $50 for Staar, in part citing upside risks and margin challenges posed by their recent acquisitions. 

Key Data  

Second Quarter 2024 Highlights 

• Net sales up 7% to US $99.0 million and up 9% to US $100.4 million in constant currency. 

• Net income of US $7.4 million or $0.15 per share vs. net income of US $6.1 million or $0.12 per share year ago. 

• Adjusted EBITDA of US $22.5 million or $0.45 per share vs. US $18.3 million or $0.37 per share a year ago. 

• Cash, cash equivalents, and investments available for sale of US $235.5 million on June 28, 2024. 

Financials 

STAAR Surgical Company has experienced significant revenue growth over the past four years, with total revenue nearly doubling from US $163.46 million in 2020 to US $322.42 million in 2023. This reflects strong demand for its innovative eye-care products, particularly the Visian ICL. Alongside this, gross profit also increased substantially, from US $118.36 million to US $252.65 million during the same period, maintaining a healthy gross margin of around 78%-80%.  

However, the company has faced rising operating expenses, particularly in Sales, General, and Administrative (SG&A) costs, which grew sharply from US $79.68 million in 2020 to US $180.15 million in 2023, driven by expanded sales and marketing efforts. Research and Development (R&D) expenses also increased, indicating continued investment in innovation. As a result of these growing costs, operating income, while up from 2020, has fluctuated, peaking at US $43.80 million in 2022 before falling to US $28.10 million in 2023.  

Net income followed a similar trend, rising from US $5.91 million in 2020 to US $39.67 million in 2022, before declining to US $21.35 million in 2023, due to higher operating expenses and increased tax liabilities. Despite these challenges, STAAR remains profitable, though future profitability will depend on the company’s ability to balance expense growth with revenue expansion while continuing to innovate in the competitive vision correction market.  

Over the past four quarters, STAAR Surgical Company has demonstrated a mix of growth and challenges. Revenue steadily increased, rising from US $76.27 million in Q4 2023 to US $99.01 million in Q2 2024, reflecting strong demand for its products. Gross profit followed this upward trend, growing from US $60.73 million to US $78.41 million during the same period, with a consistently high gross margin above 77%.  

However, operating expenses, particularly in Sales, General, and Administrative (SG&A), surged significantly, climbing from US $39.45 million in Q4 2023 to US $52.46 million in Q2 2024. This spike, alongside higher Research and Development (R&D) costs, caused fluctuations in operating income, which fell to a loss of US $2.28 million in Q1 2024 before increasing to US $11.90 million in Q2 2024.  

Net income showed similar volatility, with a loss of US $3.34 million in Q1 2024, but a recovery to US $7.38 million in the following quarter. This fluctuation highlights the pressure rising costs are placing on profitability, as the company works to balance growing sales efforts with effective cost management. 

Over the four-year period from 2020 to 2023, STAAR Surgical’s balance sheet shows notable growth in assets and equity, alongside a low and stable debt profile. Total assets nearly doubled, rising from US $257.42 million in 2020 to US $488.69 million by the end of 2023, driven primarily by increases in current assets, particularly net receivables and inventory. Cash and cash equivalents fluctuated during this period, peaking at US $199.71 million in 2021, dipping to US $86.48 million in 2022, before recovering to US $183.04 million in 2023, reflecting the company’s careful liquidity management.  

Notably, STAAR has maintained a minimal debt load, with total debt consistently under US $207,000, reflecting a conservative financial approach that reduces financial risk and dependence on borrowing. Overall, STAAR Surgical is focused on expanding its operations while maintaining a strong liquidity position. 

Right now, the EPS of the company is at US $0.43 compared to last year’s EPS of US $0.79. 

Forecast 

Right now, the company is trading at US $31.04, with a 1-year projected target of around US $47.04 and a low estimation of US $26.92; the average price target will be US $40.91. 

Technical Analysis 

• The price action analysis of the stock indicates a positive uptrend in the stock. 

• Right now, the RSI (43.07) indicator gives a positive sign, which shows it is a good time to invest in this stock. It is also giving a bullish divergence.  

• The stock has the potential to bounce back up to 30%-50% from the current market price. 

Indicators Summary- BUY 

• Market sentiment is bullish, and stocks can go up further. 

• 100 days EMA and 50 days EMA also give us a positive sign pushing the price upwards. 

• VWAP is also giving us a buy signal.

Risk factors 

There are some risks involved with STAAR Surgical Company 

• Strong competition from companies like Alcon and Johnson & Johnson Vision could reduce STAAR’s market share, especially in its key product lines. 

• STAAR’s revenue heavily depends on its Visian ICL products. Any decline in demand could significantly impact financial performance.  

• STAAR’s success depends on surgeons adopting and recommending its products, and any shift in preferences toward competing technologies could affect sales. 

• STAAR operates in a heavily regulated industry, and delays or failure to gain approvals from bodies like the FDA could affect product launches and revenue. 

Stock Recommendation 

Investing in STAAR Surgical Company presents a compelling opportunity for those interested in the medical device sector, particularly in vision correction technologies. As a pioneer in implantable collamer lens (ICL) technology, STAAR offers a unique product that is gaining recognition as an effective alternative to LASIK surgery. STAAR is actively expanding its international presence, tapping into new customer bases in markets with increasing demand for vision correction procedures, which could significantly boost revenue. 

STAAR has the financial flexibility to invest in research and development, marketing, and potential acquisitions. Additionally, STAAR’s commitment to innovation, supported by ongoing investments in R&D, promises new product introductions and enhancements to existing offerings, helping maintain its competitive edge in the industry. The global vision correction market is expected to grow due to an aging population and increased awareness of vision health. This bodes well for STAAR as more consumers seek effective solutions for refractive errors.  

STAAR Surgical Company’s strong market position, impressive financial growth, solid balance sheet, and favorable industry trends make it a recommended buy for investors. The company’s focus on innovation and global expansion positions it well for continued growth in the evolving vision correction market, making it a promising addition to a diversified investment portfolio.  

Market Facts gives a “Buy” rating on the stock at the closing price of US $31.04 as of September 25th, 2024. 

CMP (US)  (September 25, 2024)	$31.04
Target Price	$47.04
Recommendation	Buy

Disclaimer: 

The information provided in this document and the resources available for download are intended for informational purposes only and should not be interpreted as financial advice. While the content is based on thorough research and is accurate to the best of our knowledge, it is not a substitute for professional financial guidance. We strongly recommend consulting with a financial advisor to discuss your specific situation and obtain tailored advice before making any financial decisions.